Advanced Infusion Care nets limited distribution contract
By HME News Staff
Updated 11:13 AM CDT, Mon March 13, 2023
DALLAS – Advanced Infusion Care, a division of AIS Healthcare, now offers GAMMAKED, developed by Kedrion for the treatment of patients with primary humoral immunodeficiency (PI), idiopathic thrombocytopenic purpura (ITP) in adults and children, and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. This new therapy option, offered under a limited distribution contract with Kedrion, expands AIC’s ability to serve immunoglobulin (Ig) infusion patients. “We’re proud to be able to add GAMMAKED to our growing list of Ig infusion therapies,” said Jud Hall, president at AIC. “This therapy from Kedrion can help us provide additional treatment options for our patients.” The nationally accredited home infusion teams at AIC collaborate closely with physicians to provide specialized in-home infusion services. The company says, like all of its patients, those with PI, ITP and CIDP will receive a high level of care, including 24/7 access to clinical and support staff. It assigns every patient a dedicated team of professionals, including clinical pharmacists, infusion nurse specialists and intake managers to provide support throughout the treatment process. The company is dually accredited by URAC and the Accreditation Commission for Health Care.
Comments